The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:2085-2086 November 10, 2005 Number 19
NextNext

Costimulation Blockade with Belatacept in Renal Transplantation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Vincenti, F.
-PubMed Citation
To the Editor: The recent trial of belatacept in renal transplantation (Aug. 25 issue)1 reveals three cases of post-transplantation lymphoproliferative disorder. Two of the patients with the disorder had a primary Epstein–Barr virus (EBV) infection. The promise of belatacept is greater specificity in the suppression of the immune response.2 Theoretically, therefore, the use of belatacept should not prevent the development of primary immunity against EBV if the virus is introduced in patients with an allograft. It would be interesting to know from the authors whether the primary infection in these two patients was secondary to an EBV seromismatch at transplantation . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.